Key Highlights
- OneSource Specialty Pharma has entered into a strategic manufacturing partnership for global biosimilar programs.
- The company will provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing from its Bengaluru biologics facility.
- The collaboration supports biosimilar manufacturing for international markets.
- OneSource operates five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA.
- The company continues to expand its integrated biologics manufacturing capabilities as a global CDMO.
OneSource Specialty Pharma (NSE: ONESOURCE) has announced a strategic manufacturing partnership to support the production of biosimilars for global markets. The company disclosed on July 14, 2026, that it will serve as a strategic manufacturing partner by providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics manufacturing facility in Bengaluru.
According to the company's press release, the collaboration combines biosimilar development expertise with OneSource's integrated manufacturing platform to support biosimilar programs intended for international markets. The partnership reflects a shared focus on expanding access to biosimilars through scalable and quality-focused manufacturing.
Partnership Focuses on Integrated Biologics Manufacturing
As part of the partnership, OneSource Specialty Pharma will provide end-to-end manufacturing support covering both Drug Substance and Drug Product manufacturing. These activities will be carried out from the company's biologics facility in Bengaluru.
The company stated that the collaboration is designed to combine biosimilar development capabilities with integrated manufacturing expertise. By bringing together these capabilities, the partnership aims to support biosimilar programs across global markets through an integrated manufacturing approach.
The announcement did not disclose the financial value of the partnership or specify individual product programs covered under the collaboration.
Manufacturing Platform Supports Global Programs
OneSource Specialty Pharma highlighted its integrated biologics manufacturing platform, which spans multiple stages of development and commercial manufacturing. According to the company, its capabilities extend from cell line development to commercial fill-finish operations.
The company also noted that it operates five manufacturing facilities that have received approvals from leading global regulatory authorities, including the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA).
In addition to biologics manufacturing, OneSource has expertise in sterile injectables and drug-device combinations, enabling it to offer end-to-end contract development and manufacturing solutions for complex pharmaceutical products.
Partnership Aligns With Global Biosimilar Demand
The company stated that reliable, scalable and quality-focused manufacturing plays an important role in supporting the broader availability of biosimilars across international markets. According to the announcement, the collaboration is intended to support manufacturing requirements through an integrated and cost-efficient production model.
The partnership also reflects the increasing importance of specialized biologics manufacturing capabilities as pharmaceutical companies expand biosimilar development programs across multiple regions.
While the announcement outlines the strategic nature of the collaboration, the company has not disclosed any revenue estimates, production volumes, or commercial timelines associated with the partnership.
Company Highlights Integrated CDMO Capabilities
OneSource Specialty Pharma operates as a pure-play global Contract Development and Manufacturing Organization (CDMO), focusing on the development and manufacturing of complex pharmaceutical products.
Its portfolio includes biologics, sterile injectables, drug-device combinations, and oral technologies such as soft gelatin capsules. The company stated that its integrated development and manufacturing capabilities, supported by over 1,600 professionals, enable it to provide end-to-end solutions for pharmaceutical companies.
The company believes that its manufacturing infrastructure and regulatory compliance capabilities position it to support complex biologics manufacturing programs for global customers.
What Investors May Watch
Following the announcement, market participants may watch for additional updates regarding the implementation of the manufacturing partnership. Investors may also look for future disclosures relating to commercial production timelines, expansion of biosimilar programs, or any financial contribution arising from the collaboration, if disclosed by the company in subsequent regulatory filings.
As of the current announcement, the company has not provided guidance regarding the financial impact of the partnership.
Conclusion
OneSource Specialty Pharma's newly announced strategic manufacturing partnership represents another step in expanding its integrated biologics manufacturing business for global markets. By providing Drug Substance and Drug Product manufacturing through its Bengaluru facility, the company is strengthening its role as a global CDMO in the biosimilars segment. While the financial terms of the partnership have not been disclosed, the announcement highlights the company's manufacturing capabilities, regulatory-approved facilities, and integrated biologics platform supporting international pharmaceutical programs.
FAQs
Q: What did OneSource Specialty Pharma announce?
A: The company announced a strategic manufacturing partnership to support global biosimilar programs through integrated Drug Substance and Drug Product manufacturing.
Q: Where will the manufacturing activities be carried out?
A: Manufacturing will be undertaken at OneSource Specialty Pharma's biologics facility located in Bengaluru.
Q: What manufacturing services will OneSource provide?
A: The company will provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities for biosimilar programs.
Q: How many manufacturing facilities does OneSource Specialty Pharma operate?
A: According to the company, it operates five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA.
Q: Has the company disclosed the financial value of the partnership?
A: No. The company has not disclosed the financial value or expected financial impact of the strategic manufacturing partnership in its announcement.